The first flu shot of its kind is one step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for approval. The FDA’s independent vaccine advisers voted unanimously 9-0 that the benefits of Moderna’s amfluciva shot outweigh the risks in people ages 50 to 64, as well as those 65 and older. It is modern…
Please follow and like us:
